Renagel: Uses, Dosage & Side Effects
A non-absorbed oral phosphate binder used to control hyperphosphatemia in adults with chronic kidney disease on hemodialysis or peritoneal dialysis
Renagel (sevelamer hydrochloride) is a non-absorbed, cross-linked polymeric phosphate binder prescribed to lower high blood phosphate levels (hyperphosphatemia) in adult patients with chronic kidney disease (CKD) who are receiving dialysis. Unlike calcium-based phosphate binders, Renagel contains no calcium and no aluminum, which makes it particularly useful when these elements need to be avoided. Sevelamer works inside the gastrointestinal tract, binding dietary phosphate so that it passes out of the body in the stool rather than being absorbed. Controlling serum phosphate is a central part of the management of chronic kidney disease-mineral and bone disorder (CKD-MBD), helping to reduce the risk of vascular calcification, secondary hyperparathyroidism, and renal bone disease. Renagel is taken with meals and requires ongoing monitoring of blood phosphate, calcium, and bicarbonate levels.
Quick Facts: Renagel
Key Takeaways
- Renagel (sevelamer hydrochloride) is a calcium-free, aluminum-free phosphate binder that controls high blood phosphate levels in adults receiving hemodialysis or peritoneal dialysis for chronic kidney disease.
- It is not absorbed into the bloodstream and works exclusively in the gastrointestinal tract by binding dietary phosphate, which is then eliminated in the feces together with the polymer.
- Tablets must be taken whole with meals, three times a day; the dose is titrated based on regular measurements of serum phosphate, typically every 2 to 3 weeks initially and then every 3 months during maintenance.
- Gastrointestinal side effects (nausea, diarrhea, constipation, flatulence) are common, especially early in treatment, and metabolic acidosis may develop because the hydrochloride salt releases hydrogen ions in the gut.
- Renagel can reduce absorption of several medications – including ciprofloxacin, levothyroxine, mycophenolate, tacrolimus, and cyclosporine – which should be taken at least 1 hour before or 3 hours after the phosphate binder.
What Is Renagel and What Is It Used For?
Renagel contains the active substance sevelamer hydrochloride, a synthetic, cross-linked polyallylamine polymer. Sevelamer is not a drug in the traditional sense: it is not absorbed from the gastrointestinal tract into the bloodstream. Instead, it acts locally inside the intestine, where its positively charged amine groups attract the negatively charged phosphate ions from food. The sevelamer-phosphate complex formed in the gut is too large to cross the intestinal wall and is eliminated with the stool. This mechanism allows Renagel to remove dietary phosphate before it can be absorbed into the blood.
Phosphate control is a cornerstone of the management of chronic kidney disease (CKD). Healthy kidneys excrete excess phosphate in the urine, but when kidney function falls to dialysis-requiring levels, this ability is lost. Phosphate then accumulates in the blood, a state called hyperphosphatemia. Persistent hyperphosphatemia drives a cascade of disturbances collectively known as chronic kidney disease-mineral and bone disorder (CKD-MBD). Over time, elevated phosphate binds calcium, precipitates in blood vessels and heart valves, causes pathological calcifications, stimulates the parathyroid glands (secondary hyperparathyroidism), and weakens the skeleton (renal osteodystrophy). Large observational studies have consistently associated higher serum phosphate levels with increased cardiovascular mortality in dialysis patients.
Renagel is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and regulatory authorities in many other countries for the following indication:
- Control of hyperphosphatemia in adult patients on hemodialysis or peritoneal dialysis. Treatment is initiated when a low-phosphate diet alone is insufficient to keep serum phosphate within the target range recommended by international guidelines such as KDIGO (Kidney Disease: Improving Global Outcomes).
Unlike older phosphate binders, Renagel contains neither calcium nor aluminum. Calcium-containing binders (such as calcium carbonate and calcium acetate) can cause positive calcium balance, hypercalcemia, and may accelerate vascular calcification when used in high doses. Aluminum-based binders, historically used before modern alternatives, are associated with aluminum accumulation and toxic encephalopathy and are now largely avoided. Sevelamer’s calcium-free, metal-free structure makes it particularly suited to patients who are at risk of hypercalcemia, who have evidence of vascular calcification, or who have adynamic bone disease where additional calcium is undesirable.
Beyond its phosphate-lowering effect, sevelamer also binds bile acids in the intestine. This secondary action leads to modest reductions in low-density lipoprotein (LDL) cholesterol and total cholesterol, which may be clinically useful in a population with a very high cardiovascular risk. Several clinical trials, including the DCOR and RIND studies, have compared sevelamer with calcium-based binders and suggested benefits in surrogate outcomes such as coronary artery calcification progression, although the evidence on hard cardiovascular endpoints remains the subject of ongoing debate.
Renagel is chemically distinct from older phosphate binders based on calcium, magnesium, or aluminum. Its action relies on the physical and chemical properties of a high-molecular-weight polymer that remains entirely inside the gastrointestinal tract. Because no sevelamer is absorbed, the drug’s effects are confined to the gut and there is no systemic accumulation – an important advantage in patients whose kidneys cannot clear most drugs normally.
Renagel is sometimes confused with Renvela. Both are sevelamer-based medicines developed by the same manufacturer, but Renagel contains the hydrochloride salt of sevelamer, while Renvela contains sevelamer carbonate. The two differ in that Renagel can contribute a small acid load because the hydrochloride releases hydrochloric acid when it binds phosphate, potentially worsening metabolic acidosis in susceptible patients. Renvela (the carbonate salt) is generally the preferred option when acid-base balance is a concern and is additionally approved in some jurisdictions for non-dialysis CKD. Renagel remains in use where it is already well tolerated or where the carbonate form is unavailable.
What Should You Know Before Taking Renagel?
Contraindications
There are a small number of situations in which Renagel must not be used. These absolute contraindications are based on data from clinical trials and post-marketing experience.
- Hypophosphatemia: Renagel must not be used in patients with abnormally low blood phosphate (hypophosphatemia), because further lowering of phosphate could lead to muscle weakness, bone demineralization, and cardiac or respiratory complications.
- Bowel obstruction: Patients with an established bowel obstruction should not receive Renagel. Because the tablets swell in contact with fluid and increase intestinal residue, their use could worsen obstruction or precipitate perforation.
- Hypersensitivity: Do not take Renagel if you are allergic to sevelamer hydrochloride or any of the excipients in the tablet.
Warnings and Precautions
Rare but serious gastrointestinal adverse events have been reported in patients taking sevelamer, including bowel obstruction, ileus, intestinal perforation, and gastrointestinal bleeding. If you experience severe or persistent abdominal pain, marked abdominal swelling, persistent vomiting, an inability to pass stool or gas, or blood in your stool, contact your healthcare team urgently. Treatment may need to be interrupted while further evaluation is performed.
Before starting Renagel and at each follow-up appointment, inform your doctor if any of the following apply to you:
- Dysphagia or swallowing difficulties: Because the tablets are relatively large and are designed to be swallowed whole, patients with swallowing problems may have difficulty tolerating them. Very rare cases of esophageal ulceration have been reported. Alternative sevelamer formulations (e.g., the carbonate powder) may be more appropriate.
- Gastrointestinal motility disorders: Patients with severe constipation, gastroparesis (delayed gastric emptying), or other major motility disorders may be at increased risk of serious intestinal complications. Any new or worsening gastrointestinal symptoms should be reported promptly.
- Previous bowel surgery: Patients who have undergone major gastrointestinal surgery may be at higher risk of bowel obstruction or altered drug transit. Dosing and monitoring should be individualized.
- Active inflammatory bowel disease: Data in patients with Crohn’s disease or ulcerative colitis are limited, and sevelamer should generally be avoided in the presence of active inflammation.
- Metabolic acidosis: The hydrochloride form of sevelamer liberates hydrogen ions as it binds phosphate in the gut. This can contribute to or worsen metabolic acidosis, particularly in patients already prone to acidosis because of kidney failure. Serum bicarbonate should be checked periodically, and switching to the carbonate form may be considered if acidosis develops.
- Fat-soluble vitamin deficiency: Long-term use of sevelamer can reduce absorption of the fat-soluble vitamins A, D, E, and K and of folic acid. Dialysis patients already tend to have low stores of 25-hydroxyvitamin D, so most are prescribed active vitamin D analogues. Routine supplementation of vitamin K and folic acid may be considered, especially in patients with prolonged use.
- Peritonitis in peritoneal dialysis patients: Peritonitis can complicate peritoneal dialysis regardless of phosphate binder choice. Any abdominal pain, cloudy dialysate, or fever should be reported immediately.
- Dyslipidemia: Sevelamer can lower LDL and total cholesterol. This is usually considered beneficial but may influence the need for and dosing of lipid-lowering medications.
Your dialysis and nephrology team will perform regular laboratory monitoring while you are taking Renagel. Typical assessments include serum phosphate, calcium, parathyroid hormone (PTH), bicarbonate, albumin, and sometimes fat-soluble vitamin levels. Dose adjustments are guided by these values and by your clinical condition.
Other Medications
Because Renagel binds not only phosphate but also certain co-administered medications, it can reduce the absorption and effectiveness of other drugs taken at the same time. Tell your doctor and pharmacist about every medicine you are taking, including herbal remedies, vitamins, and over-the-counter products. Timing of administration is a key strategy to avoid clinically significant interactions (see the interactions section below).
Pregnancy and Breastfeeding
There are no adequate, well-controlled studies of Renagel in pregnant women. Because sevelamer is not systemically absorbed, direct fetal exposure is believed to be minimal, but animal studies have shown reductions in fetal ossification at high doses, probably reflecting effects on maternal vitamin metabolism. Renagel should only be used during pregnancy if the potential benefits justify the potential risks, and only after a detailed discussion with your nephrologist and obstetrician. If you are pregnant or planning pregnancy, make sure this is documented in your medical record.
It is not known whether sevelamer or its degradation products are excreted in human breast milk. Because the polymer itself is not absorbed, systemic transfer through milk is unlikely. Nevertheless, a decision on whether to breastfeed or to continue/discontinue Renagel should be made together with your doctor, taking into account the benefits of breastfeeding and the importance of controlling the mother’s phosphate levels.
Use in Children and Adolescents
The safety and efficacy of Renagel (the hydrochloride salt) have not been established in children and adolescents under 18 years of age. In pediatric dialysis practice, sevelamer carbonate is more commonly used because of its better acid-base profile; age- and weight-adjusted dosing must be supervised by a pediatric nephrologist.
Use in Elderly Patients
Older adults can use Renagel, but they may be more susceptible to gastrointestinal side effects, constipation, and bowel obstruction, particularly if they have reduced mobility, take other constipating medications, or have a history of diverticular disease. Dose titration should proceed cautiously, and bowel function should be monitored carefully.
Driving and Operating Machinery
Renagel has not been shown to affect the ability to drive or operate machinery. Patients should, however, be aware that the underlying chronic kidney disease and its complications can cause fatigue and concentration problems that may affect driving safety.
Important Information About Ingredients
Each 400 mg Renagel tablet contains the polymer sevelamer hydrochloride together with inactive excipients. Patients with rare hereditary intolerance to certain excipients (for example, lactose in some formulations) should discuss the product’s composition with their pharmacist. The tablets are film-coated to improve swallowing but must not be chewed, crushed, or broken.
How Does Renagel Interact with Other Drugs?
Interactions with Renagel are primarily physical and occur inside the gastrointestinal tract. The sevelamer polymer can bind to other medicinal substances, forming non-absorbable complexes that reduce the amount of active drug reaching the bloodstream. The clinical significance depends on the drug involved, its therapeutic index, and whether the patient’s response can be easily monitored. Sevelamer itself is not metabolized by cytochrome P450 enzymes, so it does not cause pharmacokinetic interactions through enzyme induction or inhibition.
Major Interactions
| Interacting Drug | Effect | Clinical Management |
|---|---|---|
| Ciprofloxacin (and other oral fluoroquinolones) | Approximately 50% reduction in ciprofloxacin bioavailability when co-administered | Separate dosing: ciprofloxacin at least 1 hour before or 3 hours after Renagel |
| Mycophenolate mofetil | Reduced exposure to the active metabolite mycophenolic acid, risking rejection in transplant patients | Separate by at least 2 hours; consider monitoring mycophenolic acid levels in transplant patients |
| Levothyroxine | Decreased absorption leading to unstable TSH and hypothyroidism | Administer levothyroxine at least 4 hours before Renagel; monitor TSH regularly |
| Tacrolimus and cyclosporine | Reduced absorption with risk of subtherapeutic levels and graft rejection | Separate by at least 1–3 hours; monitor trough blood concentrations closely |
| Amiodarone and other antiarrhythmics | Theoretical risk of reduced efficacy and breakthrough arrhythmias | Administer at least 1 hour before or 3 hours after Renagel; monitor clinical response |
| Antiepileptic drugs (e.g., phenytoin, valproate) | Potential reduction in plasma levels with risk of breakthrough seizures | Separate dosing and monitor serum drug levels where appropriate |
Other Relevant Interactions
| Interacting Drug or Supplement | Effect | Clinical Management |
|---|---|---|
| Warfarin and oral anticoagulants | Possible reduction in vitamin K absorption, which may alter the international normalized ratio (INR) | Monitor INR more frequently when Renagel is started, stopped, or dose-adjusted |
| Oral fat-soluble vitamins (A, D, E, K) | Reduced absorption with prolonged use | Monitor levels; supplement as needed, preferably separated in time from Renagel doses |
| Digoxin | No clinically significant interaction demonstrated in studies | Routine monitoring of digoxin levels as clinically indicated |
| Statins (e.g., atorvastatin, simvastatin) | No clinically significant interaction in available data | Standard lipid monitoring; sevelamer itself may lower LDL modestly |
| Oral bisphosphonates | Theoretical reduction in absorption | Separate dosing by at least 2 hours; bisphosphonates are rarely used in advanced CKD |
As a general rule, any new oral medication prescribed while a patient is taking Renagel should trigger a check of potential interactions. Patients who manage complex medication regimens are encouraged to keep a written or electronic medication schedule specifying which drugs should be taken separately from their phosphate binder. Pharmacists can help design a practical plan that is easy to follow.
What Is the Correct Dosage of Renagel?
The correct Renagel dose depends on the severity of hyperphosphatemia, the patient’s diet, body size, dialysis prescription, and clinical response. The goal is to bring serum phosphate toward the normal range (typically between 1.13 and 1.78 mmol/L, or 3.5 and 5.5 mg/dL, depending on guideline thresholds) while avoiding excessive calcium loading, maintaining adequate nutrition, and limiting side effects. Dose adjustments are made by your nephrologist based on regular blood tests and clinical assessment.
Adults
Starting Dose
Standard initiation: 2 to 4 tablets of 400 mg (800–1600 mg) with each main meal, three times daily.
Patients transitioning from calcium-based binders: Doses are generally substituted on a gram-for-gram basis, but individual titration is still required.
Severe hyperphosphatemia (>2.4 mmol/L / >7.5 mg/dL): Your doctor may start at the higher end of the range and titrate up more rapidly.
Dose Titration
The dose is adjusted at 2- to 3-week intervals based on serum phosphate values until the target is reached. A typical increment is 400–800 mg per meal (1 to 2 additional tablets) at each adjustment.
Once stable, phosphate is checked at least every 1–3 months, as recommended by KDIGO guidance for dialysis patients.
Maintenance Dose
Most adult dialysis patients maintained on Renagel require approximately 6 to 12 tablets per day (2.4–4.8 g), divided across the three main meals. Total daily doses up to 13 g have been used in clinical trials, but practical tolerability is often the limiting factor.
Children
Renagel (sevelamer hydrochloride) is not approved for use in children and adolescents under 18 years of age, and safety and efficacy data in this group are limited. When phosphate binding is required in pediatric dialysis patients, sevelamer carbonate is more commonly used under the supervision of a pediatric nephrologist, with doses individualized by body surface area and titrated carefully.
Elderly
No specific dose adjustment is required in elderly patients based on age alone. However, because older adults are more susceptible to constipation, impaction, and other gastrointestinal complications, it is often prudent to start at the lower end of the dose range and titrate slowly. Regular review of bowel function is essential.
How to Take Renagel Tablets
- With meals: Always take tablets with food, ideally at the beginning of the meal. Taking Renagel between meals is ineffective because it needs dietary phosphate in the gut to work.
- Swallow whole: Tablets must be swallowed whole with water. They must not be chewed, crushed, or broken, because they swell on contact with fluids and can be uncomfortable or cause choking.
- Consistent timing: Try to take your doses at roughly the same times each day to help establish a routine and avoid missed doses.
- Separate from interacting drugs: Follow your pharmacist’s schedule for medicines that must be separated from Renagel (see the interactions section).
Missed Dose
If you forget to take a dose with your meal, take it as soon as you remember, provided the meal is still in progress or was recently finished. If it is already close to your next meal, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for a missed one, as this increases the risk of gastrointestinal side effects without improving phosphate control.
Overdose
Because sevelamer is not absorbed, acute overdose is unlikely to produce systemic toxicity. However, very large doses may cause severe gastrointestinal symptoms including abdominal pain, vomiting, diarrhea, or, rarely, bowel obstruction. If a significantly larger-than-prescribed amount has been taken, contact your healthcare provider or local poison information center. Supportive care is the mainstay of management; there is no specific antidote.
Resist the temptation to lower or raise your Renagel dose based on how you feel. Phosphate levels are invisible to symptoms until severe and cannot be judged without laboratory testing. Your nephrology team bases dose decisions on blood tests that reflect the cumulative impact of diet, dialysis, and medication.
What Are the Side Effects of Renagel?
Like all medicines, Renagel can cause side effects, although not everyone experiences them. Because sevelamer is not absorbed into the bloodstream, systemic side effects are uncommon; most adverse events are related to its local action in the gastrointestinal tract or to downstream effects on nutrient and acid-base balance. Your dialysis team monitors you for these issues and adjusts treatment accordingly.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Dyspepsia (indigestion)
- Flatulence (excess wind)
Common
May affect up to 1 in 10 people
- Metabolic acidosis (low blood bicarbonate)
- Headache
- Hypertension (increased blood pressure)
- Hypotension (decreased blood pressure)
- Itching (pruritus)
- Rash
- Pain, including bone and joint discomfort
- Fatigue
- Modest reductions in LDL and total cholesterol (generally considered beneficial)
Uncommon
May affect up to 1 in 100 people
- Increases in serum transaminases (liver enzymes)
- Hypersensitivity reactions
- Reduced absorption of fat-soluble vitamins with long-term use (A, D, E, K)
- Reduced folic acid absorption
Rare to Very Rare
May affect up to 1 in 1,000 people or fewer
- Bowel obstruction and ileus
- Intestinal perforation
- Gastrointestinal bleeding
- Esophageal ulceration (typically linked to inadequate fluid intake with tablets)
- Diverticulitis
- Sevelamer-associated crystalline enterocolitis (reported in post-marketing surveillance)
Not Known
Frequency cannot be estimated from available data
- Angioedema
- Dermatologic hypersensitivity reactions
Managing Common Side Effects
Most gastrointestinal side effects improve within a few weeks of starting Renagel as the gut adjusts to the new polymer load. Practical strategies include taking the tablets with the first bite of food rather than after meals, ensuring adequate fluid intake (within dialysis fluid limits), and dividing the dose evenly across the three main meals. If constipation becomes a persistent problem, your dietitian and doctor can help with tailored dietary fiber recommendations and, if needed, osmotic laxatives that do not interact with sevelamer.
If metabolic acidosis is identified on routine blood work, options include increasing bicarbonate supplementation, adjusting the dialysate bicarbonate concentration, reducing the Renagel dose, or switching to sevelamer carbonate (Renvela), which does not contribute an acid load. The choice depends on how well phosphate is controlled and your overall acid-base status.
Seek urgent medical attention if you develop severe or persistent abdominal pain, an inability to pass stool or gas, persistent vomiting, abdominal swelling, blood in your stool, or signs of a severe allergic reaction (swelling of the lips, tongue, or throat; widespread hives; difficulty breathing). These symptoms may indicate rare but serious complications that require prompt assessment.
If you experience any side effects, including those not listed above, tell your doctor, pharmacist, or dialysis nurse. You can also report suspected side effects directly to your national pharmacovigilance authority (for example, the EMA network in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom), which helps regulators monitor the long-term safety profile of Renagel.
How Should Renagel Be Stored?
Correct storage is important for maintaining the tablet’s physical integrity, because sevelamer swells on exposure to moisture. The following conditions are recommended for Renagel 400 mg film-coated tablets:
- Temperature: Store below 25°C (77°F). Avoid places that may become hot, such as near radiators, ovens, or in direct sunlight.
- Moisture: Keep the container tightly closed after every opening to protect the tablets from humidity. Do not transfer tablets to another container that does not offer the same moisture protection.
- Light: No special light protection is required beyond the original container.
- Expiry date: Do not use tablets after the expiry date stated on the carton and bottle label. The expiry date refers to the last day of the month indicated.
- Children: Store Renagel out of the sight and reach of children, preferably in a locked cupboard if small children are in the household.
Do not dispose of medicines through wastewater or household waste. Ask your pharmacist how to dispose of unused or expired Renagel. These measures help protect the environment by keeping pharmaceutical substances out of water systems and ecosystems.
What Does Renagel Contain?
Active Substance
The active substance in Renagel is sevelamer hydrochloride, a high-molecular-weight cross-linked polymer of allylamine and epichlorohydrin. Each film-coated tablet contains 400 mg of sevelamer hydrochloride. The polymer is non-crystalline, water-insoluble, and not absorbed from the gastrointestinal tract.
Inactive Ingredients (Excipients)
- Anhydrous colloidal silica (silicon dioxide)
- Stearic acid
- Hypromellose (hydroxypropyl methylcellulose)
- Film-coating with diacetylated monoglycerides
- Printing ink containing iron oxide (black and/or yellow), propylene glycol, and hypromellose
The precise list of excipients for a specific Renagel product should be confirmed with the package leaflet provided in your country, as formulations may vary slightly between regions and over time.
Appearance
Renagel 400 mg film-coated tablets are typically oval, off-white, and embossed with "Renagel 400" on one side. They are supplied in high-density polyethylene (HDPE) bottles with child-resistant polypropylene closures and an induction seal to preserve dryness. Bottle sizes commonly contain 360 tablets, although other pack sizes may be available.
Marketing Authorization Holder and Manufacturer
Renagel was originally developed by GelTex Pharmaceuticals and is marketed by Genzyme Europe B.V., part of the Sanofi group. Manufacturing and distribution arrangements vary by country; details are stated on the product packaging and in the local package insert.
Frequently Asked Questions About Renagel
Renagel (sevelamer hydrochloride) is a phosphate binder prescribed for adult patients with chronic kidney disease who are receiving hemodialysis or peritoneal dialysis. It is used together with a controlled-phosphate diet and, where appropriate, active vitamin D analogues, to keep serum phosphate within the target range and to reduce the complications of hyperphosphatemia, including vascular calcification, secondary hyperparathyroidism, and renal bone disease.
Renagel tablets must be taken whole with meals. Never crush, chew, or break them, because the tablets swell when exposed to fluids and can become uncomfortable or cause choking. Take your prescribed number of tablets with the first bite of each of your three main meals and swallow with water. Consistency is important: taking Renagel between meals makes it ineffective, because the polymer only works when there is dietary phosphate in the gut.
Gastrointestinal side effects are most common: nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, and flatulence. Metabolic acidosis (lower blood bicarbonate) can develop because the hydrochloride form releases hydrogen ions during phosphate binding. Most side effects are mild or moderate and tend to improve over the first few weeks of treatment. Rare but serious events include bowel obstruction, ileus, and intestinal perforation, which require urgent medical attention.
Several drugs are less well absorbed if taken at the same time as Renagel. Ciprofloxacin, mycophenolate mofetil, levothyroxine, tacrolimus, cyclosporine, and certain antiarrhythmic and antiepileptic drugs should be separated from your phosphate binder – typically at least 1 hour before or 3 hours after (and 4 hours before for levothyroxine). Your pharmacist can build a dosing schedule around your meals so interactions are minimized. Always share your complete medication list at each appointment.
Renagel and Renvela are closely related but not identical. Both are sevelamer-based phosphate binders, but Renagel contains sevelamer hydrochloride and Renvela contains sevelamer carbonate. They lower phosphate by the same mechanism. The main difference is the acid-base effect: Renagel releases hydrochloric acid in the gut and can worsen metabolic acidosis, while Renvela does not. For that reason, sevelamer carbonate is generally preferred in patients with acidosis or when a more flexible oral powder formulation is required, and it is approved in some regions for non-dialysis CKD as well.
Long-term use of Renagel can slightly reduce the absorption of fat-soluble vitamins (A, D, E, K) and folic acid. In dialysis patients, active vitamin D analogues such as calcitriol or alfacalcidol are commonly prescribed and are unaffected by this interaction because their absorption profile and delivery routes differ. Routine monitoring can detect any deficiencies, and supplementation – typically separated in time from Renagel – can address them. Your renal dietitian will help tailor your overall nutrition plan.
Data on Renagel use during pregnancy are limited. Because sevelamer is not absorbed, direct fetal exposure is likely minimal, but animal studies have shown indirect effects on fetal development at high maternal doses. Pregnancy in women on dialysis is uncommon and requires coordinated care by a nephrology-obstetric team. The decision to continue or change phosphate binder therapy during pregnancy is individualized and must balance maternal phosphate control with theoretical risks to the fetus.
References
- European Medicines Agency (EMA). Renagel (sevelamer hydrochloride) – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). Renagel (sevelamer hydrochloride) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59.
- Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients (Treat-to-Goal Study). Kidney Int. 2002;62(1):245–252. doi:10.1046/j.1523-1755.2002.00434.x.
- Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients (RIND). Kidney Int. 2007;71(5):438–441.
- Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients (DCOR). Kidney Int. 2007;72(9):1130–1137.
- Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8:CD006023.
- Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(10):578–589.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the KDIGO 2017 clinical practice guideline update. Ann Intern Med. 2018;168(6):422–430.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in nephrology, dialysis care, and clinical pharmacology.
Medical Content
iMedic Nephrology Editorial Team – specialist physicians in nephrology with clinical experience in dialysis and CKD-MBD management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, KDIGO, and ERA-EDTA guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety in renal impairment
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.